Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review
Authors' conclusion
Genetic polymorphisms in propofol metabolism can influence the pharmacokinetics of propofol and, potentially, anaesthesia-related clinical outcomes.
Study context
- Population
- Patients undergoing propofol-based total intravenous anaesthesia (TIVA) with pharmacogenomic testing for UGT1A9, CYP2B6 and CYP2C9 genotypes
- Participants
- 1,779 patients · 16 studies
- Comparison
- UGT1A9, CYP2B6 and CYP2C9 genotypes in propofol-based TIVA
- Outcome
- Impact of metabolic genetic polymorphisms on propofol clearance, dose requirements and related clinical effects
Pooled result
As reported in the abstract
- UGT1A9 rs72551330 (98T>C) CT heterozygotes: may have lower propofol clearance, lower dose requirements and longer emergence times
- UGT1A9 rs2741045 (−440C>T) CC homozygotes: may have higher propofol clearance with faster emergence
- CYP2B6 and CYP2C9 genotypes: no apparent significant influence on propofol pharmacokinetics or anaesthesia-related clinical outcomes
Original publication
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review. Br J Anaesth. Published 6 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →